Sulphur containing pyrazole derivatives as selective cannabinoid CB
The present invention relates to sulphur containing pyrazole derivatives, and their S-oxidized active metabolites, as selective cannabinoid CB 1 receptor antagonists having a high CB 1 /CB 2 receptor subtype selectivity, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of these pyrazole derivatives, to pharmaceutical compositions comprising one or more of these pyrazole derivatives as active ingredients, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.
1. A method for treating at least one disorder in a patient in need thereof, wherein said at least one disorder is chosen from psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, stroke, spinal cord injury, neuroinflammatory disorders, plaque sclerosis, vital encephalitis, demyelinisation related disorders, neuropathic pain disorders, septic shock, glaucoma, diabetes, emesis, nausea, asthma, respiratory diseases, gastrointestinal disorders, gastric, ulcers, diarrhoea, and sexual disorders, said method comprising administering to the patient a pharmacologically effective amount of at least one compound of formula (I),
wherein:
R 1 represents H, Cl or Br,
R 2 represents Cl or Br,
X represents a sulphur atom, a sulfoxide (S═O) or a sulfone (SO 2 ) moiety,
Y represents a methyl or an ethyl group, and
n can have the value 1, 2 or 3,
or a tautomer, stereoisomer, prodrug or N-oxide thereof, or a pharmacologically acceptable salt of said compounds of formula (I), or a tautomer, stereoisomer, or N-oxide of any of the foregoing.
2. The method as claimed in claim 1 , wherein the at least one disorder is chosen from appetite disorders and obesity.
3. The method as claimed in claim 2 , wherein the at least one disorder is obesity and is chosen from juvenile obesity and drug induced obesity.
4. The method as claimed in claim 2 , further comprising administration of at least one lipase inhibitor.
5. The method as claimed in claim 4 , wherein said lipase inhibitor is orlistat or lipstatin.